ethyl 5-benzyl-1,2,4-oxadiazole-3-carboxylate | 1216803-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 5-benzyl-1,2,4-oxadiazole-3-carboxylate
• CAS: 1216803-85-8
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: RYEFZMMFDOQYCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 5-benzyl-1,2,4-oxadiazole-3-carboxylate 在 吡啶 、 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 7.34h， 生成 tert-butyl 4-((N-(4-(1,3,2-dithiarsolan-2-yl)phenyl)-5-benzyl-1,2,4-oxadiazole-3-carboxamido)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] ORGANIC ARSENIC-BASED TYPE II PYRUVATE KINASE INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] INHIBITEUR DE LA PYRUVATE KINASE DE TYPE II À BASE D'ARSENIC ORGANIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 一类基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途

  摘要：

  本发明提供了一种基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途。具体地，本发明的PKM2抑制剂为式I化合物、或其药学上可接受的盐、或其立体异构体或互变异构体、水合物或溶剂化物；其中，X1、X2、R1、R2、R3、R4、R5和n如说明书所定义。本发明的化合物对PKM2具有高抑制活性和高特异性，非常适合用于制备通过抑制PKM2通路从而抑制肿瘤的药物。

  公开号：

  WO2021254254A1
• 作为产物：
  描述：

  ethyl(E)-2-(hydroxyimino)-2-(2-phenylacetamido)acetate 在 N,N-二甲基甲酰胺 作用下， 反应 2.0h， 以81%的产率得到ethyl 5-benzyl-1,2,4-oxadiazole-3-carboxylate
  参考文献：
  名称：

  [EN] PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
  [FR] INHIBITEUR DE NÉCROSE CELLULAIRE PROGRAMMÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 一类细胞程序性坏死抑制剂及其制备方法和用途

  摘要：

  本发明提供了一类细胞程序性坏死抑制剂及其制备方法和用途。具体地，本发明提供了一种化合物，或其药学上可接受的盐、水合物或溶剂化物，其中，所述的化合物如式I所示。本发明还提供可该化合物的制备方法以及含其的药物组合物或其在治疗或预防与细胞程序性坏死和/或人受体相互作用蛋白1激酶(RIPK1)相关的疾病或病症中的用途。

  公开号：

  WO2022057787A1

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• [EN] PYRIMIDINONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINONE ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2022037585A1

  公开（公告）日：2022-02-24

  It relates to pyrimidinone compounds and uses thereof. In particular, it relates to pyrimidinone compounds of formula (I), and the pharmaceutical compositions, the preparing methods and the uses thereof, wherein the variables are as defined in the description.

  本发明涉及嘧啶酮化合物及其用途。具体而言，本发明涉及公式（I）的嘧啶酮化合物，以及制备方法、制药组合物和用途，其中变量如描述中所定义。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US08618138B2

  公开（公告）日：2013-12-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物及其用作药物的新型化合物，更具体地用于预防或治疗神经退行性疾病，更具体地用于某些神经系统疾病，如被称为tau病变的疾病和由细胞毒性α-突触核蛋白淀积引起的疾病。本发明还涉及使用所述新型化合物制备用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的制药组合物以及制备所述新型化合物的方法。
• Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases
  申请人：Katholieke Universiteit Leuven, K.U. Leuven R&D

  公开号：US20190054068A1

  公开（公告）日：2019-02-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.